Scientific Presentations A Phase 2, Randomized, Open-label Study of Onvansertib in Combination with Standard-of-Care (SoC) Versus SoC Alone for First-line Treatment of RAS-mutated Metastatic Colorectal Cancer Click to download A Phase 1b/2 Clinical Study of Onvansertib in Combination with FOLFIRI/Bevacizumab Revealed a New Role of PLK1 in regulating the Hypoxia Pathway in KRAS-mutant Colorectal Cancer … Continue reading Scientific Presentations